

ASSOCIATION BETWEEN RACE AND COVID-19 OUTCOMES IN THE UNITED STATES (2020-2021)

Sruthi Adimadhyam¹, Rebecca Hawrusik¹, Hye Seung Lee², Caroline J. Jjingo², Jane Baumblatt², Maria Kempner¹, Megan Wiley¹, Andrew Petrone¹, Yueqin Zhao², Danijela Stojanovic², Efe Eworuke², Adebola Ajao²

> ¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA ²United States Food and Drug Administration, Silver Spring, MD, USA

INTRODUCTION

- Limited early literature showed disparities in COVID-19 outcomes, such as hospitalizations, among minoritized racial groups in the United States
- Our objective was to determine the association between self-reported race and COVID-19 outcomes after controlling for differences in demographic, clinical, and socioeconomic factors at baseline

METHODS & RESULTS

- We conducted an observational **cohort study** evaluating the occurrence of hospitalization, critical COVID, and inpatient mortality in the 30 days following COVID+ diagnosis or hospitalization with COVID using longitudinal administrative data from the **Rapid COVID-19 Sentinel Distributed Database**
- 15.4% of COVID+ individuals were hospitalized within 30 days (highest in Black/AA^{*} and NHOPI[†]) 58% of individuals hospitalized with COVID developed critical COVID within 30 days of admission (highest in NHOPI^{\dagger} and Black/AA^{*}) • 14.2% of individuals hospitalized with COVID died within 30 days of admission (highest in AIAN^{*} and NHOPI[†])

• Association between race and COVID-19 outcomes was determined with White as a reference category using **multivariable logistic regression models** that controlled for demographic, clinical and socioeconomic differences at baseline

Study Design Diagrams

Evaluation of outcomes following hospitalization with COVID



Characteristics of Study Population

Evaluation of outcomes following COVID+

Adjusting for demographic & clinical Adjusting for demographic, clinical & SES factors factors

Hospitalization with COVID-19 within 30 days of COVID-19 diagnosis or positive lab result



Critical COVID within 30 days of COVID-19 hospitalization

COVID hospitalized population (n = 133,773)

COVID+ population (n = 841, 628)



• Mean age: 55.2 (oldest: NHOPI[†], 66; youngest: Asian, 48.5)

- 54% female (most: Black/AA^{*}, 61%; least: NHOPI[†] 47%)
- NHOPI⁺ had highest prevalence of coronary artery disease, liver disease, interstitial lung disease
- AIAN[‡] had highest prevalence of alcohol or drug abuse
- Black/AA^{*} had highest prevalence of hypertension, diabetes, asthma, COPD, obesity
- Asian people lived in areas with highest household
- Mean age: 71.6 (oldest: White, 75; youngest: Asian, 68)
- 49% female (most: Black/AA^{*}, 56%; least: NHOPI † 37%)
- AIAN^{*} had highest prevalence of alcohol or drug abuse, autoimmune conditions, liver disease, pulmonary conditions
- White people had highest prevalence of coronary artery disease, COPD, smoking, neurologic conditions
- Black/AA^{*} had highest prevalence of



Inpatient mortality within 30 days of COVID-19 hospitalization



hypertension, diabetes, asthma, obesity income, property value, and least unemployment *AA: African American; *AIAN: American Indian or Alaska Native; *NHOPI: Native Hawaiian or Other Pacific Islander

CONCLUSION

• After controlling for demographic, clinical and socioeconomic differences at baseline, **minoritized groups** had **increased odds** for **hospitalization** and **mortality** following COVID-19 relative to their White counterparts in the United States in the first year of the pandemic

LIMITATIONS

- Self-reported race was not known for a significant portion of the sample
- Residual confounding by socioeconomic and other clinical factors such as biomarkers not adequately captured in administrative claims data
- Data represent association between race and COVID-19 outcomes among the commercially insured population in the US

ACKNOWLEDGEMENTS/DISCLOSURES

- Presented at the 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 2023, Halifax, Nova Scotia, Canada
- This work was supported by Task Order 75F40119F19001 under Master Agreement 75F40119D10037 from the United States Food and Drug Administration (FDA). The views expressed represent those of the author(s) and do not necessarily represent the official views of, nor an endorsement by FDA/HHS. Or the U.S. Government
- The authors have no conflicts of interest to disclose
- Many thanks are due to data partners who provided data used in the analysis:
 - CVS Health Clinical Trial Services (Aetna), Blue Bell, PA; Kaiser Permanente Colorado Institute for Health Research, Aurora, CO; Humana Healthcare Research Inc., Louisville, KY;
- Efe Eworuke and Jane Baumblatt were employees of the Food and Drug Administration during the time of study conduct
- Analytic programming and full set of study results are published on the Sentinel website:

